These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 23727861

  • 1. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.
    Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL, Pandolfi PP.
    Nat Genet; 2013 Jul; 45(7):739-746. PubMed ID: 23727861
    [Abstract] [Full Text] [Related]

  • 2. Genetics: ZBTB7A suppresses castration-resistant prostate cancer.
    Razzak M.
    Nat Rev Clin Oncol; 2013 Aug; 10(8):427. PubMed ID: 23774644
    [No Abstract] [Full Text] [Related]

  • 3. ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer.
    Han D, Chen S, Han W, Gao S, Owiredu JN, Li M, Balk SP, He HH, Cai C.
    Cancer Res; 2019 Oct 15; 79(20):5260-5271. PubMed ID: 31444154
    [Abstract] [Full Text] [Related]

  • 4. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
    Manda KR, Tripathi P, Hsi AC, Ning J, Ruzinova MB, Liapis H, Bailey M, Zhang H, Maher CA, Humphrey PA, Andriole GL, Ding L, You Z, Chen F.
    Oncogene; 2016 Jun 23; 35(25):3282-92. PubMed ID: 26477312
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
    Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, Rosivatz E, Woscholski R, Cognetti F, Scher HI, Pandolfi PP.
    J Clin Invest; 2010 Mar 23; 120(3):681-93. PubMed ID: 20197621
    [Abstract] [Full Text] [Related]

  • 10. Leveraging the species barrier to advance cancer therapy.
    Zhao S, Nelson PS.
    Nat Genet; 2013 Jul 23; 45(7):718-20. PubMed ID: 23800864
    [Abstract] [Full Text] [Related]

  • 11. PTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo.
    Parisotto M, Grelet E, El Bizri R, Dai Y, Terzic J, Eckert D, Gargowitsch L, Bornert JM, Metzger D.
    J Exp Med; 2018 Jun 04; 215(6):1749-1763. PubMed ID: 29743291
    [Abstract] [Full Text] [Related]

  • 12. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
    Redmer T, Raigel M, Sternberg C, Ziegler R, Probst C, Lindner D, Aufinger A, Limberger T, Trachtova K, Kodajova P, Högler S, Schlederer M, Stoiber S, Oberhuber M, Bolis M, Neubauer HA, Miranda S, Tomberger M, Harbusch NS, Garces de Los Fayos Alonso I, Sternberg F, Moriggl R, Theurillat JP, Tichy B, Bystry V, Persson JL, Mathas S, Aberger F, Strobl B, Pospisilova S, Merkel O, Egger G, Lagger S, Kenner L.
    Mol Cancer; 2024 May 29; 23(1):114. PubMed ID: 38811984
    [Abstract] [Full Text] [Related]

  • 13. Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.
    Burdelski C, Bujupi E, Tsourlakis MC, Hube-Magg C, Kluth M, Melling N, Lebok P, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Wilczak W, Simon R, Schlomm T, Steurer S, Krech T.
    PLoS One; 2015 May 29; 10(6):e0128525. PubMed ID: 26030748
    [Abstract] [Full Text] [Related]

  • 14. Loss of JUNB/AP-1 promotes invasive prostate cancer.
    Thomsen MK, Bakiri L, Hasenfuss SC, Wu H, Morente M, Wagner EF.
    Cell Death Differ; 2015 Apr 29; 22(4):574-82. PubMed ID: 25526087
    [Abstract] [Full Text] [Related]

  • 15. ZBTB7A suppresses glioblastoma tumorigenesis through the transcriptional repression of EPB41L5.
    Jeong JH, Park SH, Kim H, Nam HY, Kim SH, Jeong M, Kong MJ, Son J, Jeong JE, Song JH, Kim SW, Choi KC.
    Exp Mol Med; 2023 Jan 29; 55(1):43-54. PubMed ID: 36596853
    [Abstract] [Full Text] [Related]

  • 16. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C, Ci X, Sun X, Fu X, Zhang Z, Dong EN, Hao ZZ, Dong JT.
    Neoplasia; 2014 Nov 29; 16(11):883-99. PubMed ID: 25425963
    [Abstract] [Full Text] [Related]

  • 17. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
    Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X.
    J Clin Invest; 2013 Mar 29; 123(3):1109-22. PubMed ID: 23426182
    [Abstract] [Full Text] [Related]

  • 18. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
    Higgins J, Brogley M, Palanisamy N, Mehra R, Ittmann MM, Li JZ, Tomlins SA, Robins DM.
    Horm Cancer; 2015 Jun 29; 6(2-3):67-86. PubMed ID: 25631336
    [Abstract] [Full Text] [Related]

  • 19. LZTS2 and PTEN collaboratively regulate ß-catenin in prostatic tumorigenesis.
    Yu EJ, Hooker E, Johnson DT, Kwak MK, Zou K, Luong R, He Y, Sun Z.
    PLoS One; 2017 Jun 29; 12(3):e0174357. PubMed ID: 28323888
    [Abstract] [Full Text] [Related]

  • 20. Emerging role of ZBTB7A as an oncogenic driver and transcriptional repressor.
    Gupta S, Singh AK, Prajapati KS, Kushwaha PP, Shuaib M, Kumar S.
    Cancer Lett; 2020 Jul 28; 483():22-34. PubMed ID: 32348807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.